User: Guest  Login
Document type:
journal article 
Märten, A; Schmidt, J; Ose, J; Harig, S; Abel, U; Münter, MW; Jäger, D; Friess, H; Mayerle, J; Adler, G; Seufferlein, T; Gress, T; Schmid, R; Büchler, MW 
A randomized multicentre phase II trial comparing adjuvant therapy in patients with interferon alpha-2b and 5-FU alone or in combination with either external radiation treatment and cisplatin (CapRI) or radiation alone regarding event-free survival - CapR 
BACKGROUND: The 5-year survival of patients with resected pancreatic adenocarcinoma is still unsatisfying. The ESPAC-1 and the CONKO 001 trial proofed that adjuvant chemotherapy improves 5-year survival significantly from approximately 14% to 21%. In parallel, investigators from the Virginia Mason Clinic reported a 5-year survival rate of 55% in a phase II trial evaluating a combination of adjuvant chemotherapy, immunotherapy and external beam radiation (CapRI-scheme). Two other groups confirmed...    »
Journal title abbreviation:
BMC Cancer 
Journal volume:
Pages contribution:
TUM Institution:
Chirurgiesche Klinik und Poliklinik; II. Medizinische Klinik und Poliklinik